Literature DB >> 26115788

Three Turkish families with different transthyretin mutations.

Can Ebru Bekircan-Kurt1, Nalan Güneş2, Arda Yılmaz3, Sevim Erdem-Özdamar4, Ersin Tan4.   

Abstract

Transthyretin (TTR)-related hereditary amyloidosis, also called familial amyloid polyneuropathy (FAP), is a rare autosomal dominant systemic disorder that presents with progressive axonal sensory, autonomic and/or motor neuropathies. The present report describes three families with three different TTR mutations who were followed from 1995 to 2014. Only one of these families expressed the Val30Met mutation, which is the most common mutation in endemic regions; all members of this family had late disease onset but varied severities and clinical presentations of the disease. The second family expressed the Thr49Ser mutation, which has not been well documented previously. Our limited experience obtained from these patients indicates that this mutation presents with autonomic neuropathy but a greater degree of cardiac involvement, especially fatal heart failure. The third mutation, Glu54Lys, has been identified as a cause of severe familial amyloid polyneuropathy; the family members with this mutation exhibited severe motor and autonomic neuropathy, early vitreous opacity, and fatal heart failure. Three of the patients with the Val30Met mutation were treated with tafamidis for longer than one year and cessation of the polyneuropathy resulted. However, a short trial of tafamidis in two patients with the Glu54Lys mutation, who showed severe systemic and neurological involvement, did not gain any clinical benefits.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Familial amyloid polyneuropathy; Glu54Lys; Thr49Ser; Transthyretin; Val30Met

Mesh:

Substances:

Year:  2015        PMID: 26115788     DOI: 10.1016/j.nmd.2015.05.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

1.  Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90.

Authors:  Javier Oroz; Jin Hae Kim; Bliss J Chang; Markus Zweckstetter
Journal:  Nat Struct Mol Biol       Date:  2017-02-20       Impact factor: 15.369

2.  Lumbar Spinal Stenosis: A Rare Presentation of Hereditary Transthyretin Amyloidosis.

Authors:  Arman Çakar; Murat Mert Atmaca; Dilcan Kotan; Hacer Durmuş; Feza Deymeer; Piraye Oflazer; Yeşim Parman
Journal:  Noro Psikiyatr Ars       Date:  2020-10-11       Impact factor: 1.339

Review 3.  Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series.

Authors:  Márcia Waddington-Cruz; Hartmut Schmidt; Marc F Botteman; John A Carter; Michelle Stewart; Markay Hopps; Shari Fallet; Leslie Amass
Journal:  Orphanet J Rare Dis       Date:  2019-02-08       Impact factor: 4.123

4.  Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.

Authors:  Hartmut H Schmidt; Márcia Waddington-Cruz; Marc F Botteman; John A Carter; Avijeet S Chopra; Markay Hopps; Michelle Stewart; Shari Fallet; Leslie Amass
Journal:  Muscle Nerve       Date:  2018-02-01       Impact factor: 3.217

5.  Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.

Authors:  Daniel Serrano; Christopher B Atzinger; Marc F Botteman
Journal:  Neurol Ther       Date:  2018-04-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.